AI and Annotated Medical Images – OpenPath, PLIP, and “Medical Twitter”

By Michael Awood

September 1, 2023

The lack of available annotated medical images has historically hindered healthcare innovation. However, a solution is emerging as healthcare professionals start to share anonymised images and insights on public platforms – which includes the social media site previously known as Twitter (X). This has led to the creation of OpenPath, a comprehensive dataset of over 200,000 pathology images coupled with natural language descriptions, marking it as the largest public dataset of its kind.

Researchers have used OpenPath to develop Pathology Language–Image Pre-training (PLIP), a multimodal AI trained on this dataset. PLIP has demonstrated impressive results in zero-shot learning and transfer learning for classifying new pathology images across various tasks. Additionally, PLIP enables users to locate similar cases using either image or natural language search, encouraging knowledge sharing.

The researchers collected over 240,000 public pathology images using popular pathology-related hashtags and expanded the collection with data from other online sources. After thorough data quality checks, they assembled over 200,000 pathology image-text pairs named OpenPath, which they used to develop the versatile PLIP.

PLIP outperformed previous models in tasks such as zero-shot learning, linear probing, and text-to-image and image-to-image retrieval. Unlike other digital pathology machine learning methods, PLIP can adapt to new datasets and provide zero-shot predictions based on any text input, making it a flexible tool for potential new disease subtypes.

The study did note some limitations, including irrelevant data in the image-text pairs and challenges in accounting for varying magnification levels and staining styles. However, researchers are optimistic that PLIP can adjust to images with diverse magnification levels and staining protocols. They expect that OpenPath and PLIP will significantly contribute to advancing AI in pathology and encourage a data-focused approach in this area.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.